HTAs and rare diseases: How to assess their cost-effectiveness

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	161-165
Journal	Pharmaceuticals Policy and Law
Volume	13
Issue number	3-4
DOIs	https://doi.org/10.3233/PPL-2011-0321
Publication status	Published - 1 Nov 2011

Access to Document

Evidence-based policies for new medicines
Hughes, D. (Participant), Linley, W. (Participant), Tunnage, B. (Participant) & Yeo, S. T. (Participant)
Impact: Policy and Public Services

File

@article{c5841112872240e6a866e1ba3f8d807a,

title = "HTAs and rare diseases: How to assess their cost-effectiveness",

author = "D. Hughes and C.J. Phillips and D.A. Hughes",

year = "2011",

month = nov,

day = "1",

doi = "10.3233/PPL-2011-0321",

language = "English",

volume = "13",

pages = "161--165",

journal = "Pharmaceuticals Policy and Law",

issn = "1389-2827",

publisher = "IOS Press BV",

number = "3-4",

}